Colonoscopy

Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection

Retrieved on: 
Wednesday, March 20, 2024
Colonoscopy, LCI, Documentation, Adenoma, EYE, Colorectal cancer, Conditional sentence, Risk, White Light, Polyp, APC, Assist, AI, Woman, Workflow, System, Safety, Swedish Health Services, Endoscopy, FDA, Health, CAD, Medical device

Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.

Key Points: 
  • Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.
  • CAD EYE® enables real-time detection of colonic mucosal lesions such as polyps and adenomas during colonoscopy procedures, supporting endoscopists in their ability to detect and remove pre-cancerous lesions, regardless of size, shape and color.
  • Consisting of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02), CAD EYE is an evolution of Fujifilm’s ELUXEO® Endoscopic Imaging System, featuring AI image processing functionality customized for the integration with the system’s processor and the endoscope.
  • CAD EYE, ELUXEO and LCI are registered trademarks of FUJIFILM Corporation in various jurisdictions.

Dxcover invited to present its CREATE-2 clinical trial for the early detection of colorectal cancer and advanced adenoma at the American Association for Cancer Research Annual Meeting 2024 in San Diego CA April 10

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Colonoscopy, Algorithm, Survival, Colorectal cancer, Patient, Cancer, Quality of life, FTIR, Machine learning, Blood, Fourier, Medical imaging

The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.

Key Points: 
  • The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.
  • The prospective observational study has two recruitment pathways, one in the US (targeting 1000 patients) and one in the UK (targeting 700 patients).
  • CREATE-2 intends to validate the previous feasibility study results from CREATE-1 which showed Dxcover’s ability to achieve accurate detection of pre-cancerous lesions and stage 1 colorectal cancer.
  • Dxcover’s Multi-Omic Spectral Analysis (MOSA-Dx™) enables analysis the full complement of signals within the blood to provide early detection of cancer.

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Retrieved on: 
Wednesday, March 13, 2024
Health, Oncology, Clinical Trials, Medical Supplies, Harvard Medical School, Colonoscopy, Colorectal cancer, Helmy Eltoukhy, Survival rate, Massachusetts General Hospital, Cancer, Risk, Patient, Ageing, Evaluation, American Cancer Society, Neoplasm, Perception, DNA, MD, Circulating tumor DNA, Hospital, PMA, CRC, Large intestine, Multimedia, FDA, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240313547689/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240313547689/en/
    Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk.
  • (Photo: Business Wire)
    “Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,” said AmirAli Talasaz, Guardant Health co-CEO.
  • The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).
  • One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield.

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Medical Supplies, Health, Medical Devices, Other Health, General Health, Clinical Trials, Colonoscopy, Conditional sentence, Colorectal cancer, Alaska Natives, Webcast, Patient, Mayo Clinic, FIT, Exact sciences, Research, History, Cancer, CRC, Carcinoma, Pharmaceutical industry

“Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.

Key Points: 
  • “Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.
  • BLUE-C investigators also collected blood samples for evaluation of a blood-based CRC screening test developed by Exact Sciences.
  • This enrollment diversity helps ensure that the BLUE-C findings and Cologuard Plus are relevant for all screen-eligible individuals, regardless of race or ethnicity.
  • ET to discuss results of the pivotal BLUE-C study.

Ambetter from Sunshine Health and Tampa Bay Buccaneers Tackle Colorectal Cancer During Colorectal Cancer Awareness Month

Retrieved on: 
Tuesday, March 26, 2024
Health, Colonoscopy, Colorectal cancer, Disease, Partnership, Risk, American Cancer Society, African Americans, Football, Research, Death, Bucs, CNC, Woman, Super, Buccaneer, Super Bowl, Large intestine, Centene Corporation, PSA, Tampa Bay Buccaneers

TAMPA, Fla., March 26, 2024 /PRNewswire/ -- As Colorectal Cancer Awareness Month continues throughout March, Ambetter from Sunshine Health and the Tampa Bay Buccaneers are teaming up to spread awareness about colorectal cancer by unveiling a powerful public service announcement (PSA). The video featuring Shelton Quarles, Buccaneers Director of Football Operations and former Super Bowl-winning linebacker for the team, is aimed at raising awareness about the importance of preventive screenings.

Key Points: 
  • TAMPA, Fla., March 26, 2024 /PRNewswire/ -- As Colorectal Cancer Awareness Month continues throughout March, Ambetter from Sunshine Health and the Tampa Bay Buccaneers are teaming up to spread awareness about colorectal cancer by unveiling a powerful public service announcement (PSA).
  • Through this joint effort, Ambetter from Sunshine Health and the Buccaneers are committed to sharing vital health information that has the potential to make a profound impact in the fight against colorectal cancer.
  • Colorectal cancer is the second most common cause of cancer deaths in the United States in both men and women.
  • Additionally, colorectal cancer disproportionately affects Black Americans , who are 20% more likely to get colorectal cancer and about 40% more likely to die from it than other groups.

Capital Digestive Care Launches AI-Driven LGI-Flag Algorithm for Predicting Lower Gastrointestinal Disorders Including Colorectal Cancer in the United States

Retrieved on: 
Tuesday, March 12, 2024
Colonoscopy, Disease, Colorectal cancer, Risk, USPSTF, Patient, CBC, Roche, FIT, Capital, Mid-Atlantic (United States), United, IBD, Inflammatory Bowel Diseases, Woman, Excellence, IBS, EHR

Available through the Roche navify Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.

Key Points: 
  • Available through the Roche navify Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.
  • "Capital Digestive Care is committed to enabling the digital transformation of healthcare, in order to provide a more personalized, convenient and predictive continuum-of-care for patients," said Michael Weinstein, M.D., CEO of Capital Digestive Care.
  • Now, we have a means to more precisely identify those at high risk of lower GI disorders, including colorectal cancer so they may avoid the devastating effects of the disease through increased screening and earlier detection and treatment."
  • "This helps advance that mission by offering a highly effective and clinically validated machine-learning-based algorithm to identify those at increased risk of a wide array of lower GI disorders, including colorectal cancer."

Fujifilm Receives 510(k) Clearance for SCALE EYE®, a Novel Endoscopic Imaging Technology for Measuring Colonic Lesions

Retrieved on: 
Monday, February 26, 2024
Polyp (medicine), Colonoscopy, FDA, Polyp, EYE, Risk, Fujifilm, Colorectal polyp, PMID, Malignancy, Instrument, Subjectivity, NYU Langone Health, SCALE, Neoplasm, Hepatology

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, has been granted FDA 510(k) clearance for SCALE EYE, a new endoscopic imaging technology and part of its expanding ELUXEO Endoscopic Imaging System.

Key Points: 
  • LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, has been granted FDA 510(k) clearance for SCALE EYE, a new endoscopic imaging technology and part of its expanding ELUXEO Endoscopic Imaging System.
  • Measurement time was 2.8 seconds using SCALE EYE, compared to 8 seconds when measuring with forceps.
  • Comparing size measurement of colorectal polyps using a novel virtual scale endoscope, endoscopic ruler or forceps: A preclinical randomized trial.
  • Introduction and preliminary evaluation of novel endoscope with pinpoint laser technology for adequate size estimation of colon lesions.

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health Technology, Health, Oncology, Anxiety, Education, Colorectal cancer, Colonoscopy, Physician, FDA, Pain, Gastroenterology, Colorectal Cancer Alliance, CRC, Perception, Survival rate, Fear, Patient, The Harris Poll, Helmy Eltoukhy, Cancer, Online shopping

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.
  • The survey polled 1,000 American adults age 45-84, along with 351 physicians (250 primary care providers and 101 gastroenterologists).
  • In the United States, CRC screening guidelines recommend that all people of average risk begin screening starting at age 45.
  • Ultimately, 96% of all physicians surveyed would recommend an FDA-approved blood test to their patients for CRC screening.

Olympus and the Colorectal Cancer Alliance Offer a Reminder About the Importance of Preventive Cancer Screenings

Retrieved on: 
Tuesday, March 5, 2024
Large intestine, PCP, Incidence, American Cancer Society, Woman, Texture, Gastroenterology, Colorectal cancer, Colonoscopy, TXI, Physician, Extrapyramidal system, ADR, Polyp, Colorectal Cancer Alliance, CRC, FIT, Learning, Risk, Adenoma, Health, History, USPSTF, Cancer, Patient, Diagnosis, CCA, Medical imaging

CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.

Key Points: 
  • CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.
  • More than 20 years ago, colorectal cancer (CRC) was known to be the fourth-leading cause of cancer death in men and women under the age of 50, according to the American Cancer Society.
  • Now, CRC is the leading cause of cancer death for men under the age of 50 and the second leading cause for women under 50.
  • Colorectal cancer is preventable, and the power to prevent it rests in your hands."

Olympus Affirms Commitment to Health Equity Through Allyship

Retrieved on: 
Thursday, February 29, 2024
Black History Month, African Americans, OCA, Colorectal cancer, Multimedia, Education, Colonoscopy, African, Empathy, Health, Cancer, Black, ERG, The Harris Poll, Health equity, Diagnosis

CENTER VALLEY, Pa., Feb. 29, 2024 /PRNewswire/ -- During Black History Month, Olympus Corporation of the Americas (OCA) emphasized the importance of allyship in promoting equitable access to healthcare for all communities.

Key Points: 
  • Issues of health equity are crucial to Black Americans due to historical, social, and systemic factors that have led to disparities in healthcare access, outcomes, and overall well-being.
  • As an employer and a leading provider of medical technologies used for colon cancer detection, diagnosis and treatment, Olympus practices allyship through coverage of colonoscopy for all Olympus employees.
  • "Allyship is the act of supporting and advocating for people who have not had equal access to valuable resources such as healthcare.
  • During Black History Month, Olympus celebrated the ongoing contributions and resilience of its employees to build allyship.